bacTRL 1L 12
Alternative Names: bacTRL-1L-12Latest Information Update: 28 Mar 2024
At a glance
- Originator Symvivo
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours in Canada (IV)
- 01 Feb 2021 bacTRL 1L 12 is available for licensing as of 01 Feb 2021. https://www.symvivo.com/
- 01 Feb 2021 Phase-I clinical trials in Solid tumours in Canada (IV) (Symvivo pipeline, February 2021)